Demystifying Tumor Genomics

In the landscape of molecular profiling assays, the SureSelect Cancer CGP (Comprehensive Genomic Profiling) assay stands out as a tool that provides high performance. This state-of-the-art technology – built to unravel the genetic intricacies of solid tumor samples – is helping to unlock new realms of possibility to help advance precision oncology.

The SureSelect Cancer CGP assay possesses capabilities to detect a spectrum of clinically relevant somatic variants, from single nucleotide variants (SNVs) and copy number variations (CNVs) to insertions and deletions (indels), DNA translocations, as well as de novo gene fusions from RNA. It is also capable of diving deeper – setting sights on immuno-oncology biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI).

But what distinguishes the SureSelect Cancer CGP assay is its integration of assaying both DNA and RNA from a tumor sample. By allowing simultaneous sequencing of DNA from 679 genes and RNA from 80 genes – all within a single sequencing run – laboratory scientists are able to uncover key classes of somatic alterations at the molecular level.

At the heart of the assay lies SureSelect XT HS2 technology – a hybrid capture library preparation and target enrichment method that prioritizes efficiency and low sample input. The SureSelect Cancer CGP assay’s seamless integration with the Agilent Magnis NGS Prep system provides much-needed practicality as well as automation – offering streamlined workflows and as little as 15 minutes of hands-on time. And with the ability to perform enzymatic fragmentation and bead clean-up, cumbersome physical shearing equipment is no longer required, further simplifying the process with automation. The technology takes just nine hours to generate NGS sequencing-ready libraries.

Inspired by the growing need for greater speed in cancer research, Agilent has created a powerful tool that combines efficiency, performance, and flexibility – empowering laboratories across the globe. The SureSelect Cancer CGP assay is for research use only and not for use in diagnostic procedures.